Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry R Davis

Showing results (161-170 of 185) with videos related to

Pageof 19
Sort By:
BMC Medical Research Methodology|October 18, 2021
Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trialsLisa J Woodhouse, Alan A Montgomery, Jonathan Mant, et al.
Pediatric Cardiology|April 8, 2022
Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome (CHILD Study)Sunjay Kaushal, Joshua M Hare, Aakash M Shah, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 12, 2012
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFRMahboob Rahman, Charles E Ford, Jeffrey A Cutler, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|July 30, 2013
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)Karen L Margolis, Barry R Davis, Charles Baimbridge, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 5, 2013
Author response to lipid-lowering in African Americans in ALLHAT-optimism bias?Karen L Margolis, Barry R Davis, Charles Baimbridge, et al.
Circulation|October 5, 2011
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)Linda B Piller, Sarah Baraniuk, Lara M Simpson, et al.
American Journal of Hematology|December 1, 2015
Effects of hydroxyurea treatment for patients with hemoglobin SC diseaseLori Luchtman-Jones, Sara Pressel, Lee Hilliard, et al.
Circulation|September 5, 2002
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trialDavid R Holmes, Michael Savage, J-M LaBlanche, et al.
European Heart Journal|January 11, 2019
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitusGijs F N Berkelmans, Soffia Gudbjörnsdottir, Frank L J Visseren, et al.
Annals of Internal Medicine|September 10, 2020
Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension : A Systematic Review and Individual Participant-based Meta-analysisStephen P Juraschek, Jiun-Ruey Hu, Jennifer L Cluett, et al.
Pageof 19

Showing results (161-170 of 185) with videos related to

Sort By:
Pageof 19
BMC Medical Research Methodology|October 18, 2021
Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trialsLisa J Woodhouse, Alan A Montgomery, Jonathan Mant, et al.
Pediatric Cardiology|April 8, 2022
Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome (CHILD Study)Sunjay Kaushal, Joshua M Hare, Aakash M Shah, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 12, 2012
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFRMahboob Rahman, Charles E Ford, Jeffrey A Cutler, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|July 30, 2013
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)Karen L Margolis, Barry R Davis, Charles Baimbridge, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 5, 2013
Author response to lipid-lowering in African Americans in ALLHAT-optimism bias?Karen L Margolis, Barry R Davis, Charles Baimbridge, et al.
Circulation|October 5, 2011
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)Linda B Piller, Sarah Baraniuk, Lara M Simpson, et al.
American Journal of Hematology|December 1, 2015
Effects of hydroxyurea treatment for patients with hemoglobin SC diseaseLori Luchtman-Jones, Sara Pressel, Lee Hilliard, et al.
Circulation|September 5, 2002
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trialDavid R Holmes, Michael Savage, J-M LaBlanche, et al.
European Heart Journal|January 11, 2019
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitusGijs F N Berkelmans, Soffia Gudbjörnsdottir, Frank L J Visseren, et al.
Annals of Internal Medicine|September 10, 2020
Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension : A Systematic Review and Individual Participant-based Meta-analysisStephen P Juraschek, Jiun-Ruey Hu, Jennifer L Cluett, et al.
Pageof 19